HIV Infections Clinical Trial
Official title:
Measurement of Adherence to ART in HIV-Infected School-Aged Children in Uganda
This study will compare methods of determining whether HIV-infected children take their medications.
HIV is a virus that weakens people's immune systems and can cause AIDS. Antiretroviral
therapy (ART) is a treatment for HIV that combines different types of antiretroviral
medications, but it must be taken throughout a person's life without missing doses to be
effective. When people do miss doses, the HIV virus has an opportunity to develop resistance
to the medications, making them less effective in the future. Reports indicate that as many
as 50% of children infected with HIV who are living in resource-limited countries regularly
miss doses of their ART. This study will test different methods for determining children's
rates of adherence to ART medications. This will both define the exact magnitude of the
problem and direct future efforts in increasing ART adherence in children.
Participation in this study will last 12 months. All children enrolled will undergo a series
of assessments of medication adherence. At baseline and every month over the course of the
study, researchers will make unannounced home visits to measure the amount of medicine that
remains untaken by participants and to record how many times the electronic cap on
participants' medication bottles have been removed. Participants with cell phones will also
receive monthly phone calls during which they will be asked to measure the amount of their
medicine that remains untaken. At study entry and after 6 and 12 months, researchers will
also examine child participants' medical records and the results of their regularly
scheduled blood tests. At these blood tests, an additional half teaspoon of blood, which may
be used in future testing, will be collected and stored by the researchers. After 3, 6, 9,
and 12 months, researchers will request to collect hair samples from child participants to
test levels of HIV medications in the hair, but participation in this part of the study is
optional.
Assessments of reasons for medication adherence will also be performed. At study entry and
after 3, 6, 9, and 12 months, children and their parents will complete questionnaires about
their understanding of HIV medicines and HIV infection, motivation for the child to take
medications, behaviors related to taking medications, and basic personal information. One
and 7 months after study entry, some parent participants will also complete interviews with
study staff about giving HIV medicines to their children.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |